contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nordhealth-oy-nordhealth-to-accelerate-ai-development-and-dach-localisation

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

NordHealth operates in the technology industry. The company specializes in developing software for digital health. The software is developed in-house and is mainly used in the healthcare sector. Customers consist of corporate customers operating in various sectors such as hospitals, clinics, veterinarians. In addition to the main business, various value-added services are also offered. The largest operations are found in the Nordic region.

NordHealth

Helsinki, Finland - August 13, 2025 - Nordhealth is increasing its investments in product development for AI and DACH localisation in 2025:1. Accelerating the localisation of flagship veterinary...

Helsinki, Finland - August 13, 2025 - Nordhealth is increasing its investments in product development for AI and DACH localisation in 2025:1. Accelerating the localisation of flagship veterinary practice management software, Provet Cloud, into DACH markets: The company believes that the market for veterinary enterprise clients in DACH is increasingly compelling. Additionally, the company believes that the evolving differences in service quality and profitability, between Provet Cloud, and Nordhealth's acquired DACH legacy platform, Vetera, justify accelerating the groundwork to migrate Vetera clients onto Provet Cloud.2. Development of AI features across both of Nordhealth's Veterinary and Therapy business units: Based on the early results of our AI-scribe trials in Therapy, and an enhanced AI-roadmap across both business units, Nordhealth believes the return on investment of AI development will justify the increased expenditure.The total increases in product &nbsp;development expenditure from 2024 to 2025 are expected to be around €3.1M.As a result of these investments, Nordhealth is revising its 2025 target for `Adj. EBITDA - CAPEX' from `between -€2.0M and +€2.0M', to `between -€4.0M and -€2.0M'.Nordhealth's growth guidance remains unchanged: The company continues to anticipate between 12% and 17% growth in `Vet + Therapy recurring revenue' in 2025 compared to 2024, calculated at a constant currency rate as of December 31, 2024.&nbsp;&nbsp;Cash and cash equivalents in the Nordhealth Group as at 30 June 2025 (including amounts invested in money market funds), is €20.5M.A full update on the business and its growth initiatives will be provided in the Q2 Investor Presentation on Aug 19, 2025.For further information, please contact:Charles MacBain, Group CEO, charles.macbain@nordhealth.com, +44 75 3903 2200Alexander Cram, Group CFO, alexander.cram@nordhealth.com, +32 470 69 30 20This stock announcement includes inside information pursuant to article 7 of the EU Market Abuse Regulation and was published in accordance with section 5-12 of the Norwegian Securities Trading Act by Alexander Cram, Group CFO on the date and time indicated above.<div></div>